Cell Therapy News/Articles, page-17890

First 17890 Last

Share
Profile

Follow
nippy

12,091 Posts.

756

11/08/24

13:32

Post #: 75158307
Share

Originally posted by JB1975: ↑

I picked up your reference - col69 (a person who I'd hope has a below decks cabin) on this ship - and be handcupped to quite a few others - constantly flogs that line - do you remember the original post of mine that actually did think there was a typo even.

I say this because you have been a person who is short and pithy with their posts and doesn't normally attack other posters - you have been rare on hotcopper in that on balance I think your contribution has been positive not self indulgent.

In vivo and in vitro are not used inappropriately in my view in this post - reg's faith that the IL-2R potency assay wasn't used before though is clearly incorrect as any checking of the MSB submission to ODAC using the wayback machine can make clear - MSB has ALWAYS used both TNFR1 and Il2Ralpha.

I am watching the patent applications - an application is not a patent granted. It seems that if I don't post for a while people that don't even tick if I reply to their questions start to try to use some of what I've taught them.

My attitude - there is a lot of people that are going to deserve what they get that are holders on this forum. Character matters.

People of low character - set the bar low.

I'll ask this as a question - Silviu Itsecu was looking for a BLA in August 2020 and got a CRL in October 2020. Eric Rose made public information about a potency assay having problems in May 2022 (could have been 3).

Two questions - do you think Silviu would have been ignorant of the potency assay problem Eric spoke about in May years later at the time of ODAC? Do you think he would have not gone ahead and shipped product that may not have been potent to children even if he was confident its wasn't harmful?

The financial incentives here are a problem in my opinion when coupled to the character of the man. I think the FDA should not dare trust him. He should have to produce evidence ahead of not after a granted BLA because of how he conducts himself in the public sphere. That is my opinion. He can't be trusted to do the right thing - on his own honor- unless he is under close scrutiny to ensure he does. And overwhelmingly that also applies to his supporters here. Medicines would be crap if the objectivity of MSB holders was the standard. The holders themselves would get crap when they need it because their own standards of decency and objectivity - generalised over other people - would have killed them.

Expand

Fancy describing compassionate use for years as bad behaviour.

Fancy describing shareholder's going with non toxic treatment with great 4 year survival data as being of low character as well.

Some mothers do have em.

MSB Price at posting: 95.0¢ Sentiment: Buy Disclosure: Held
17 Upvote

2 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

GHY

Gold Hydrogen reports "world leading helium purities" at Ramsay Project

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

JBY

James Bay latest lithium player to pivot to other metals amidst lithium slump

KNB

Koonenberry boosts portfolio with gold and copper-gold plays in NSW

There are more pages in this discussion • 429 more messages in this thread...

First 17890 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.40		Change 0.020(1.45%)		Mkt cap ! $1.569B

Open	High	Low	Value	Volume
$1.40	$1.41	$1.38	$979.0K	701.3K

Buyers (Bids)

No.	Vol.	Price($)
5	115806	$1.39

Sellers (Offers)

Price($)	Vol.	No.
$1.40	6077	3

View Market Depth

No.	Vol.	Price($)
4	7717	1.395
8	138838	1.390
11	88339	1.385
14	154704	1.380
12	97963	1.375

Price($)	Vol.	No.
1.400	10273	5
1.405	24948	8
1.410	121107	8
1.415	70769	6
1.420	82419	6

Last trade - 10.43am 17/10/2024 (20 minute delay)

MSB (ASX) Chart

Cell Therapy News/Articles, page-17890

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Gold Hydrogen reports "world leading helium purities" at Ramsay Project

Battery Age Minerals gets set to capitalise on critical mineral demand

James Bay latest lithium player to pivot to other metals amidst lithium slump

Koonenberry boosts portfolio with gold and copper-gold plays in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Cell Therapy News/Articles, page-17890

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Gold Hydrogen reports "world leading helium purities" at Ramsay Project

Battery Age Minerals gets set to capitalise on critical mineral demand

James Bay latest lithium player to pivot to other metals amidst lithium slump

Koonenberry boosts portfolio with gold and copper-gold plays in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News